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The Bcl-2 family of proteins participates in the control of the 
cell’s commitment to programmed cell death via the mitochon-
drial  or  intrinsic  apoptotic  pathway.  Certain  proteins  in  this 
family, including Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and Bfl-1/A1, 
inhibit apoptosis, whereas others in this family promote apopto-
sis. Proapoptotic Bax and Bak appear to be indispensible for 
apoptosis (Lindsten et al., 2000; Wei et al., 2001). How does 
the cell determine fate in the face of competing pro- and anti-
apoptotic  proteins?  The  rheostat  model  proposed  that  when 
there were more antiapoptotic proteins than proapoptotic pro-
teins, the cell survived and vice versa. However, in many cases, 
the conversion of a living cell to one committed to death occurs 
without significant change in the levels of pro- and antiapop-
totic proteins. The participation of a third class of proapoptotic 
proteins largely explained this riddle. These proteins, so-called 
BH3-only as they share homology only in the proapoptotic Bcl-2 
homology 3 domain, appear to act as sentinels of cell damage, 
which convert initial perturbations into death signals, that act in 
the mitochondrial pathway. Now, Gallenne et al. (see p. 279 
of this issue) provide mechanistic insight into how the BH3-
only protein Puma promotes apoptosis. The authors find that 
Puma, like the BH3-only proteins Bim and Bid, directly acti-
vates Bax.
A key event in the commitment to apoptosis is Bax- and 
Bak-mediated permeabilization of the outer mitochondrial mem-
brane. For this to occur, Bax and Bak alter their conformation 
from an inactive to an active form, form homo-oligomers in the 
membrane, and contribute to the formation of pores, which 
allows the egress of proapoptotic proteins to the cytosol (Fig. 1). 
Although there is consensus that Bax and Bak must shift from 
an inactive to an active state for this to occur, there is less 
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consensus about what specific factors cause this crucial switch 
(Willis et al., 2007). Bid and Bim have been shown to cause 
activation (conformational change and oligomerization) of Bax 
and Bak in cellular, mitochondrial, and liposomal systems (Wei 
et al., 2000; Kuwana et al., 2002; Cartron et al., 2004; Certo 
et al., 2006). Direct interaction between these activators and 
Bax  has  been  established  experimentally  (Gavathiotis  et  al., 
2008; Lovell et al., 2008). Additional studies have suggested 
that p53 itself may translocate to the mitochondria and activate 
Bax after select stimuli (Mihara et al. 2003; Chipuk et al., 2004). 
Even heat has been indicted as a potential activating factor 
(Pagliari et al., 2005). It is quite possible that many activating 
factors remain to be discovered.
Antiapoptotic proteins inhibit apoptosis by binding pro-
apoptotic factors. In many cases, the proapoptotic factors are 
activator  BH3-only  proteins  like  Bid  and  Bim.  However,  in 
some cases, the proapoptotic factors may also include activated 
monomeric Bax and Bak, which are intercepted before they can 
oligomerize and form pores. Cells have been described in which 
antiapoptotic proteins are loaded with abundant prodeath pro-
teins as being “primed for death.” Such cells are particularly 
sensitive to treatment with chemotherapy and antagonists of   
antiapoptotic proteins like ABT-737 (Certo et al., 2006; Deng 
et al., 2007). In most cells, the vast majority of Bax and Bak are 
in the inactive form, and activated Bax and Bak can be difficult 
to detect in the absence of toxic perturbation. Nonetheless, BH3-
only molecules, which lack the ability to directly activate Bax 
or Bak, can cause apoptosis by competing for binding to anti-
apoptotic proteins (Fig. 1). If this competition frees sufficient 
activator proteins (or activated Bax and Bak), oligomerization 
of Bax and Bak ensues, committing the cell to death. Based on 
performance in assays on mitochondria and artificial liposomes 
spiked with Bax, the BH3-only family has thus been segregated 
into two subfamilies: the sensitizers and the activators.
Where does Puma fit in? Puma was initially identified as 
a p53-regulated gene that was induced after DNA damage 
(Nakano and Vousden, 2001). It has subsequently been found 
that Puma is responsible for much of the proapoptotic effect of 
p53 induction but that Puma can also cause apoptosis in a p53-
independent fashion (Jeffers et al., 2003; Villunger et al., 2003). 
The assignment of Puma as either a sensitizer or an activator has 
been somewhat contentious. The BH3 domains of BH3-only 
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enhancement of Bax killing. It is worth noting that this inter-
action site on Bax, first identified by this group 4 yr ago, over-
laps with an interaction site of the activator Bim BH3 peptide 
with Bax recently demonstrated by nuclear magnetic resonance 
in solution (Gavathiotis et al., 2008). The fact that two groups 
independently identified a similar and unexpected site for inter-
action of activating BH3 domains with Bax lends some confi-
dence to this finding.
Additionally, because the Bcl-2 family is absent from the 
yeast genome, the authors exploit yeast to study Puma and Bax 
in a setting uncontaminated by the contribution of unmeasured 
Bcl-2 family proteins. Again, they find that coexpression of 
Puma is necessary for efficient killing by Bax. Finally, the au-
thors investigate the participation of Puma in killing human 
colorectal cancer cells with ABT-737. ABT-737 is a BH3 mi-
metic that promotes apoptosis by binding antiapoptotic proteins 
and displacing select prebound prodeath proteins. Thus, ABT-
737 can only kill cells that are primed with either activators 
or preactivated Bax or Bak. They find that ABT-737 treatment 
proteins are both necessary and sufficient to interact with Bcl-2 
family members and seem to largely recapitulate function of the 
entire protein. For instance, the BH3 domains of Bid and Bim 
can activate Bax and Bak in liposomal or mitochondrial set-
tings. The Puma BH3 domain lacked this function in several 
studies, leading many to classify Puma as a sensitizer (Kuwana 
et al., 2005; Certo et al., 2006). However, experiments with the 
full-length protein translated in vitro show an ability to activate 
Bax comparable with that of Bim and Bid (Kim et al., 2006).
Cartron et al. (2004) has previously found that the BH3 
domains of Bim and Puma but not the sensitizer Bad interact 
with Bax and cause its activation. In Gallenne et al. (2009), the 
role of Puma as an activator is further supported by three main 
pieces of evidence. First, Bax preincubated with the Puma BH3 
peptide is more toxic to microinjected cells than is Bax alone. This 
enhancement is blocked by coincubation with a peptide mimick-
ing the putative interaction site on Bax, the H1 C-terminal pep-
tide. This suggests that the interaction of the Puma BH3 domain 
with a site on the first  helix of Bax is necessary for Puma’s 
Figure 1.  Control of mitochondrial permeabilization by Bcl-2 family proteins. Activated Bax or Bak are available to oligomerize either when they are 
directly activated by activating factors, including activator BH3-only proteins (top), or when preactivated Bax or Bak are displaced from antiapoptotic pro-
teins by either activator or sensitizer BH3-only proteins (bottom). Gallenne et al. (2009) provide evidence that Puma is an activator rather than a sensitizer. 
Oligomerized Bax or Bak participate in forming a pore that allows egress of proapoptotic factors like cytochrome c. Cytochrome c promotes formation 
of the apoptosome complex, which causes activation of effector caspases. These proteases cleave many key cellular proteins to bring about the apoptotic 
phenotype. Figure adapted with permission from the Journal of Cell Science (Brunelle, J.K., and A. Letai. 2009. J. Cell Sci. 122:437–441).191 PUMA STRIKES BAX • Letai
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results in the freeing of Puma, which then interacts with Bax,   
correlating with the death of the cell. This finding suggests that 
Puma can play the priming function that is likely critical to sen-
sitivity to many chemotherapeutic agents as well as ABT-737 
(Deng et al., 2007). This role may be particularly important in 
cells in which Bim and Bid are not expressed at high levels.
Some questions remain. It is not clear why several labo-
ratories have consistently failed to observe an activating func-
tion for the BH3 domain of Puma in either mitochondrial or 
liposomal systems. It is possible that even if Puma can play an 
activating role, the efficiency of this function may vary con-
siderably according to context and perhaps be much less in 
many contexts than that of Bid or Bim. In a full-length Puma 
protein, perhaps interactions of the Puma BH3 domain with 
Bax are enhanced. It is also possible that unknown posttrans-
lational modifications of Puma or Bax, varying according to 
cellular context, significantly influence the ability of Puma to 
activate Bax. In any case, Gallenne et al. (2009) have strength-
ened the case for Puma as an activator so that its potential 
contribution to this function cannot be ignored. One must now 
wonder: what other activators might still be out there waiting 
to be discovered?
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